Arthrosi Therapeutics

Arthrosi Therapeutics is a clinical-stage biotech company focused on developing a therapy for gout and chronic kidney disease. Its lead drug candidate, AR882, has demonstrated promising results in lowering uric acid levels and treating gout, including tophaceous gout, in clinical trials. The company aims to provide a new era of gout treatment that can effectively reduce flares and tophi, addressing the unmet needs of the large population of gout patients.